Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.4852W HIGH $5.72
Volume
1.15 M
Value Traded
5.32 M
Short % Float
0.18%
Days to Cover
1.0
+8.62%Week
-8.98%1 Month
-13.86%3 Month
-14.18%6 Month
-94.52%5 Year
-89.41%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.05 B
EPS (TTM)
0.72
P/E Ratio
6.52
Ent. Value
601.64 M
Total Shares
224.38 M
Float Shares
224.38 M
Insiders
57.58%
Institutions
3.57%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
CVAC Catalyst Timeline
Dated clinical, regulatory and corporate events for CureVac N.V.
Past FDA Catalysts and PDUFA Decisions
How CVAC actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|
Clinical Trial Results
Readouts, endpoints and source filings for every CVAC program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| seasonal influenza mRNA vaccine | seasonal influenza | Phase 2 | 2024-09-12 | positive immune responses to A and B strains, meeting all predefined success criteria in the tested age groups of older and younger adultsRead More | CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program Phase 2 data demonstrated positive immune responses to A and B strains, with acceptable safety and reactogenicity profile, Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| No insider trades match the selected filters. | |||||
Hedge Fund 13F Activity
Hedge Funds invested in CVAC
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 0.1 % (-50 %) | 5.96 M | 1.97 M | -28.37% ( -778.56 K) |
Ownership Trends
CVAC Short Interest
Shares sold short, counted twice a month.
0.18%
Short % of Float
of tradable shares sold short
395.4K
Shares Sold Short
-27.8% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
1.5M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CVAC ranks across every disease it competes in
Competitive Position is a premium feature
See how CVAC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCVAC News
About CureVac N.V.
BIOPHARMAWATCH ELITE PLUS
Trade the next CVAC catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime